− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues o...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...
- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater...
Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...
Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...
Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recu...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 27, ...
Pierre Boulud, Chief Executive Officer of bioMérieux, set the tone for the company’s first-half 2025 performance: “With a stron...
Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above out...
Group sales revenue up 6.1 percent in the first six months As expected, continued positive trend in recurring business with consumables Bioproce...
Net sales increased organically by 2.5% to € 5.3 billion EBITDA pre up organically by 5.8% to € 1.5 billion All three b...
Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Inventiva , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
© 2026 Biopharma Boardroom. All Rights Reserved.
